Redefining CML care at Novartis @Novartis
Redefining CML care at Novartis  @Novartis
Uploaded October 2026 | Updated November 2026, 3 hours ago
Some moments stay with you.

For Insa Gathmann, it was seeing early data in the late 1990s that suggested something unprecedented was happening. At first, it felt almost too good to be true.

Nearly three decades later, as she proudly retires from Novartis after an extraordinary 30+ year career, the lead biostatistician looks back on a targeted therapy that helped transform chronic myeloid leukemia treatment and redefine what was possible for many patients living with the disease.

Learn more: bit.ly/4iiALY4
Redefining CML care at NovartisWhat does belonging mean to you? Lalit’s storyPast Present & Future of CAR-TTaking out cancer’s trashCelebrating International Volunteer Day 2022 - #ThankYouVolunteersRaise Your Voice: Speaking Up About Living With Lung CancerWellbeing starts with me, you, usHow mini is a mini-heart?Novartis Strategic Business Deals in 2023Madrid is calling, and we’ve arrived for ESCCongress.Next Generation Scientist 2022Committed to make salary ranges transparent for all candidates
Novartis |

Redefining CML care at Novartis

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER